Skip to main content

Sulfacetamide sodium/urea topical Pregnancy and Breastfeeding Warnings

Brand names: Carmol Scalp, Carmol Scalp Treatment, Carmol Scalp Treatment Kit, Rosula NS

Sulfacetamide sodium/urea topical Pregnancy Warnings

Sodium sulfacetamide-urea topical has been assigned to pregnancy category C by the FDA. Animal studies have not been reported. There are no controlled data in human pregnancy. The manufacturer recommends the use of sodium sulfacetamide-urea topical for use during pregnancy only if clearly indicated and benefit outweighs risk.

See references

Sulfacetamide sodium/urea topical Breastfeeding Warnings

There are no data on the excretion of sodium sulfacetamide-urea topical into human milk. The effects in the nursing infant are unknown. The manufacturer recommends caution be used when administering sodium sulfacetamide-urea topical to nursing women.

See references

References for pregnancy information

  1. Product Information. Carmol Scalp (sulfacetamide sodium-urea topical). Doak Dermatologics Division. 2022.
  2. Product Information. Rosula NS (sulfacetamide sodium-urea topical). Doak Dermatologics Division. 2022.

References for breastfeeding information

  1. Product Information. Carmol Scalp (sulfacetamide sodium-urea topical). Doak Dermatologics Division. 2022.
  2. Product Information. Rosula NS (sulfacetamide sodium-urea topical). Doak Dermatologics Division. 2022.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer